Jyske Bank (OTC:JYSKF) Stock, Quote.Headers.trade-ideas

Jyske Bank AS is engaged in banking activities. Its subsidiaries provide other financial or accessory services. The company conducts mortgage-credit activities through Jyske Realkredit. The group's primary focus is Danish small and midsize enterprise and retail clients. Through its retail and commercial banking activities, Jyske offers a full range of financial services. Its segment consists of Banking Activities, Mortgage Activities, and Leasing Activities. The company operates in Denmark and Germany, where it earns the majority of its revenue from Denmark.

Jyske Bank AS

Alliance Global Partners analyst Gaurav Mehta initiates coverage on Chatham Lodging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLDT#NYSE">CLDT</a>) with a Buy rating and announces Price Target of $12.

News

Price Target

Initiation

Analyst Ratings

CLDT

Alliance Global Partners Initiates Coverage On Chatham Lodging with Buy Rating, Announces Price Target of $12

WIIM

UnitedHealth Group shares are trading lower. Suspect Luigi Mangione is receiving sympathy on social media, which may prompt changes in the company's business practices.

Lake Street analyst Frank Takkinen initiates coverage on InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) with a Buy rating and announces Price Target of $5.

NSPR

Lake Street Initiates Coverage On InspireMD with Buy Rating, Announces Price Target of $5

As we edge toward another year&#8217;s end, I contemplate the peculiar theater of financial markets, where the loudest voices rarely signal the best opportunities.
While pundits engage in their annual ritual of predictions (most of which will age about as well as milk left on a summer porch) and political rhetoric reaches fevered heights, I have been quietly exploring the corners where others forget to look.
I leave the prediction of doom and certain war or endless sunshine and domestic tranquility to those who choose dogma and tribes over profits and wealth-building.
In these overlooked spaces, particularly in the fixed-income markets, something rather fascinating is unfolding. The mortgage securities market &#8211; both residential and commercial &#8211; presents what I would call a &#8220;students of history&#8221; opportunity. You know the kind I mean: where market psychology creates the sort of disconnects that make value investors sit up a bit straighter in their chairs.
Let us break this down methodically, shall we? The current landscape for mortgage-backed securities (MBS) and mortgage REITs offers what I would describe as a thoughtful investor&#8217;s opportunity.
It is not the kind that makes for an exciting cocktail party conversation, mind you, but the sort that tends to compound quite nicely over time.
Mortgages are never going to be as exciting as AI, quantum computing, and nuclear fusion.
Of course, mortgages also have measurable, reliable cash flows, and a margin of safety that hope and dream stocks cannot offer.
Consider the structural elements at play.
We are seeing higher yields on both agency and jumbo MBS, creating what you might call a foundation of opportunity.
The real beauty here lies in the dramatic reduction of prepayment risk. With interest rates where they are, the refinancing wave has receded, making cash flows more predictable than they have been in quite some time.
This is where it gets interesting: residential mREITs are trading at notable discounts to net asset value. This is not the kind of discount that suggests imminent doom but rather the type that historically appears when markets paint with too broad a brush. As the Fed approaches what appears to be the end of its hiking cycle, these discounts may well normalize, offering potential capital appreciation alongside those already attractive yields.
It is not just residential mortgages that offer high-yielding opportunities to book high long-term total returns in this environment.
The commercial real estate angle adds another layer to this story. Traditional banks, particularly our regional friends, have created a financing vacuum in the CRE space, totaling $500 billion.
Nature and markets both abhor a vacuum, and we are seeing sophisticated players like KKR and Ares Management step into this space with notably interesting solutions.
December 15th: Learn why the most obvious trading signals usually fail, and what seasoned pros look for instead. R<a href="https://bzresearch.myclickfunnels.com/earnings-gaps-masterclass-registration/?utm_source=WebRD-1211">EGISTER NOW FOR FREE</a>
The private equity-backed CMBS REITs deserve special attention here.
Let me share an observation about the peculiar nature of market psychology—how it creates fascinating pockets of opportunity in the spaces between perception and reality. It&#8217;s rather like watching the tide slowly recede, revealing hidden treasures that were there all along, merely concealed by the rushing waters of collective anxiety.
Consider the current landscape of real estate investment, particularly sophisticated mortgage-backed vehicles. We&#8217;re witnessing something of an evolutionary leap here, a transformation that most market participants, caught in the undertow of headline risk and historical bias, have yet to appreciate fully.
These modern incarnations of real estate investment vehicles represent a fascinating intersection of institutional sophistication and market inefficiency. Imagine, if you will, a scenario where some of the sharpest minds in private equity &#8211; those architects of complex value creation &#8211; have turned their attention to transitional properties. Yet, the broader market remains fixated on outdated narratives about real estate risk.
The irony here is delicious: in their rush to avoid anything touching real estate, market participants have created precisely the kind of inefficiency that sophisticated investors dream about. We are seeing 8-15% yields in high-quality mortgage portfolios not because of some hidden catastrophic risk, but because of what we might call a &#8220;perception premium&#8221;, that gap between what something is and what the market thinks it is.
There is a certain philosophical beauty to this situation. The fundamental backdrop remains as solid as the properties&#8217; foundations: the eternal dance of supply and demand in housing continues its imbalanced waltz, institutional investors maintain their never-ending quest for yield, and the regulatory framework provides a steady drumbeat of stability. Yet here we are, watching the market engage in what future historians might well describe as a collective exercise in missing the forest for the trees.
For the patient investor, and let us pause here to really consider the profound importance of patience in a world increasingly devoid of it, this creates what we might call a &#8220;multiple horizons of opportunity&#8221; scenario. The immediate gratification of substantial yields provides a sort of philosophical anchor, while the longer-term potential for valuation normalization offers what some might call a free option on market rationality.
In many ways, the overreaction we are currently witnessing in real estate-related investments is a perfect case study in market psychology. It is as if the market, in its infinite capacity for pendulum-like swings between greed and fear, has temporarily forgotten that cycles are, by definition, cyclical.
This temporary amnesia creates a window, not just for profit, but for the kind of thoughtful, deliberate positioning that tends to look obvious in retrospect. As with so many things in life and markets, the key lies not in fighting the current narrative but in recognizing its transient nature and positioning oneself accordingly.
For those willing to embrace the complexity, to look beyond the surface-level narratives and into the deeper structures of opportunity, the current market environment offers a rare chance to be compensated handsomely for thinking independently while others react emotionally.
In the end, isn&#8217;t that what sophisticated investing is really about?
Not just seeing what others miss, but having the patience and perspective to act on it.
Now, if you will excuse me, I believe I hear opportunity knocking, quietly, as it tends to do in markets like these.
<a href="https://bzresearch.myclickfunnels.com/earnings-gaps-masterclass-registration/?utm_source=WebRD-1211">Transform Volatility Into Predictable Profits</a>
Image via Shutterstock

Opinion

Trading Ideas

Where to Find 15% High-Yield Opportunities Right Now

Lake Street analyst Jacob Stephan downgrades MoneyLion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>) from Buy to Hold and lowers the price target from $109 to $82.

Downgrades

Lake Street Downgrades MoneyLion to Hold, Lowers Price Target to $82

GE Vernova shares are trading higher. JP Morgan maintained their Overweight rating on the stock and raised its price target from $356 to $367. Evercore also maintained its Outperform rating and raised its price target from $385 to $390.

MP Materials's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) short percent of float has fallen 4.13% since its last report. The company recently reported that it has 19.85 million shares sold short, which is 13.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 10.04 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>MP Materials Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733942723_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for MP Materials has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing MP Materials's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, MP Materials's peer group average for short interest as a percentage of float is 3.88%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into MP Materials's Recent Short Interest

Halozyme Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NYSE">HALO</a>) short percent of float has fallen 18.07% since its last report. The company recently reported that it has 8.57 million shares sold short, which is 9.16% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.35 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Halozyme Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733942717_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Halozyme Therapeutics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Halozyme Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Halozyme Therapeutics's peer group average for short interest as a percentage of float is 12.13%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

HALO

(HALO) - Analyzing Halozyme Therapeutics's Short Interest

Marsh &amp; McLennan's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) short percent of float has fallen 11.34% since its last report. The company recently reported that it has 3.49 million shares sold short, which is 0.86% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.86 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Marsh &amp; McLennan Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733942712_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Marsh &amp; McLennan has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Marsh &amp; McLennan's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Marsh &amp; McLennan's peer group average for short interest as a percentage of float is 2.81%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(MMC) - Analyzing Marsh & McLennan's Short Interest

BNY CEO Vince, On Crypto Assets, Says Anything New Needs To Be "Battle Tested"; Says We See A Lot Of Promise In AI

RBC Capital analyst Maurice Choy reiterates Keyera (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KEY#TSX">KEY</a>) with a Outperform and raises the price target from C$45 to C$46.

Reiteration

TSX:KEY

RBC Capital Reiterates Outperform on Keyera, Raises Price Target to C$46

Ollie&#8217;s Bargain Outlet Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading higher on Wednesday.</a>
Yesterday, the company reported third-quarter adjusted earnings per share of 58 cents, <a target="_blank" href="https://www.benzinga.com/news/earnings/24/12/42417381/ollies-bargain-outlet-beats-on-q3-earnings-but-comps-dip-as-growth-strategy-shifts-gear" rel="noreferrer noopener">beating the street view of 57 cents</a>. Quarterly sales of $517.43 million (+7.8%) beat the analyst consensus of $517.36 million. The increase in net sales was the result of new store unit growth. Comparable store sales, however, decreased by 0.5%, a decline from the prior year&#8217;s increase of 7.0%.
RBC Capital Markets analyst Steven Shemesh reiterated the Outperform rating on the stock, raising the price forecast to $130 from $120.
The analyst notes that the impact of the liquidation was less severe than expected, and the guidance for the fourth quarter indicates strong underlying sales trends.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42414647/chinese-stocks-sink-on-weak-trade-data-they-rushed-to-get-goods-to-the-us-before-new-tariffs-are-imposed" rel="noreferrer noopener">Chinese Stocks Sink On Weak Trade Data Amid Rush &#8216;To Get Goods To The US&#8217; Before Tariffs</a>
Per Shemesh, a 10% unit growth in 2025 is more achievable. This reduces some of the risks and suggests potential market share gains in 2025. Approximately 205 Big Lots, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BIGGQ#OTC">BIGGQ</a>) stores, located near Ollie&#8217;s Bargain locations are set to close, most likely by the end of the fourth quarter.
Overall, the analyst projects continued progress, resulting in strong earnings growth and modest multiple expansion.
As a result, the analyst revises the fourth-quarter sales growth estimate to +3.0% (previously +2.0%) and adjusts earnings per share to $1.22 (from $1.17).
For 2025 and 2026, the analyst maintains sales growth projections at +3.5% and +2.0%, with adjusted EPS estimates of $3.92 and $4.35, respectively (up from $3.84 and $4.28).
Truist Securities analyst Scot Ciccarelli reiterated the Buy rating on the stock, raising the price forecast to $121 from $109.
The analyst highlights that the company&#8217;s third-quarter results were strong despite challenges such as a flyer shift, competitor closures, and hurricanes.
The company also reaffirmed its full-year guidance. Gross margins improved, rising back above 40%, which should ease concerns from the previous quarter, the analyst adds.
While competitor store closures may continue to be a short-term challenge in the fourth quarter, these closures could present long-term opportunities for increased sales and market share.
Additionally, Ollie&#8217;s is actively acquiring locations from bankruptcies, Ciccarelli adds.
Overall, unit growth remains robust, operational performance is solid, and the company&#8217;s value-focused offering is gaining traction with consumers facing inflation, the analyst notes.
The analyst writes that Ollie&#8217;s is benefiting from its strong value proposition, as cost-conscious consumers prioritize getting the best deal.
Price Action: OLLI shares are trading higher by 3.09% to $114.46 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42409492/teslas-2nd-best-week-in-china-in-2024-boosts-q4-prospects" target="_blank" rel="noreferrer noopener">Tesla&#8217;s 2nd Best Week in China In 2024 Boosts Q4 Prospects</a></li>
</ul>

Analyst Color

Equities

Markets

Movers

General

BIGGQ

OLLI

Ollie's Set For Strategic Expansion: Analysts Bullish As Store Growth And Market Dynamics Drive Earnings Upside

Loop Capital analyst Anthony Chukumba maintains Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) with a Buy and raises the price target from $110 to $120.

Loop Capital Maintains Buy on Ollie's Bargain Outlet, Raises Price Target to $120

Adobe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) will be reporting its fourth-quarter earnings on Wednesday. Wall Street expects $4.66 in EPS and $5.54 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=ADBE" target="_blank" rel="noreferrer noopener"> after market hours</a>.
The stock is down 12.33% over the past year, up 18.46% over the past six months.
Let&#8217;s look at what the charts indicate for Adobe stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/24/12/42440806/adobe-q4-earnings-preview-analyst-says-investors-may-be-missing-healthy-subscriber-growth">Adobe Q4 Earnings Preview: Analyst Says Investors May Be Missing Healthy Subscriber Growth</a>
<h1 class="wp-block-heading">Adobe Stock In Strong Bullish Trend Ahead Of Q4 Earnings&nbsp;</h1>
Adobe stock is painting a strongly bullish picture on the technical charts. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="627" height="487" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/11124458/Screenshot-2024-12-11-at-11.06.58-PM.png" alt="" class="wp-image-687958" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/11124458/Screenshot-2024-12-11-at-11.06.58-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/11124458/Screenshot-2024-12-11-at-11.06.58-PM-300x233.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121124&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Trading at $548.30, Adobe stock is cruising comfortably above its five-, 20- and 50-day exponential moving averages, reinforcing the uptrend despite a touch of selling pressure. With the eight-day simple moving average (SMA) at $537.93, 20-day SMA at $522.90, 50-day SMA at $506.38 and 200-day SMA at $516.20, all indicators signal a bullish momentum.
The moving average convergence/divergence (MACD) at 11.50 adds to the optimism, while the relative strength index (RSI) at 66.42 suggests Adobe stock is edging closer to overbought territory. If this trend holds, Adobe could keep printing gains in the near term.
<h1 class="wp-block-heading">Adobe Analysts See Upside</h1>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/ADBE/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Adobe stock stands at an Outperform currently with a price target of $607.46 a share. The latest analyst ratings from Citigroup, BMO Capital and RBC Capital imply a 9.37% upside for Adobe stock, with an average price target of $600.
ADBE Price Action: Adobe stock was trading up 0.46% at $548.55 a share at the time of publication.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/12/42432367/us-futures-mixed-as-street-brace-for-inflation-data-analyst-says-2024-will-go-down-as-the-best-election-year-return-ever">US Futures Mixed As Street Brace For Inflation Data: Analyst Says 2024 Will Go Down As The &#8216;Best Election Year Return Ever&#8217;</a></li>
</ul>
Photo: Shutterstock

Technicals

Previews

Tech

ADBE

Adobe Charts Signal Strength: Analysts See 9.37% Upside Ahead Of Q4 Earnings

Luigi Mangione, who is being charged with the <a href="https://www.benzinga.com/general/health-care/24/12/42316904/unitedhealthcare-ceo-brian-thompson-fatally-shot-outside-nyc-hotel">Dec. 4 murder</a> of UnitedHealthcare CEO Brian Thompson, apparently kept a diary of sorts.
Law enforcement officials who <a href="https://www.benzinga.com/general/health-care/24/12/42398524/person-of-interest-named-in-unitedhealthcare-ceos-murder-ghost-gun-found">arrested Mangioni in Pennsylvania</a> on Monday found not only a ghost gun and false IDs, they also discovered a handwritten note and a spiral notebook detailing his plans and a militantly expressed motive for Thompson&#8217;s shooting, <a href="https://www.nytimes.com/2024/12/11/nyregion/luigi-mangione-assassination-plan-notebook.html?campaign_id=190&amp;emc=edit_ufn_20241211&amp;instance_id=141940&amp;nl=from-the-times&amp;regi_id=136109156&amp;segment_id=185442&amp;user_id=e415429009fa21c5b8b4141c24d72bca">reported</a> the New York Times Wednesday, citing local police officials. 
<h2 class="wp-block-heading">For Starters, Kill A CEO</h2>
"What do you do? You wack the C.E.O. at the annual parasitic bean-counter convention. It's targeted, precise and doesn't risk innocents," was one passage in the notebook, officials said. 
Thompson was shot and killed outside a UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) investor day event. UnitedHealthcare is the insurance unit of UnitedHealth Group. 
After Mangione was arrested after being <a href="https://www.benzinga.com/general/restaurants/24/12/42427146/pennsylvania-mcdonalds-where-unitedhealthcare-ceo-murder-suspect-arrested-gets-review-bombed-more-like-narc-donalds">recognized by customers and employees</a> at a McDonalds (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NASDAQ">MCD</a>) in Altoona, Pennsylvania, authorities found a 262-word handwritten note, which seemed to be construed as taking responsibility for shooting Thompson on a midtown Manhattan street.
According to a New York Police Department internal report, which referred to Mangione&#8217;s note as a manifesto, the 26-year-old suspect viewed Thompson's murder as a "symbolic takedown," per the NY Times. The NYPD opined that Mangione "likely views himself as a hero of sorts who has finally decided to act upon such injustices" and expressed concern that others might see him as a "martyr and an example to follow."
<h2 class="wp-block-heading">Fingerprints Match Up</h2>
Local<a href="https://ktvl.com/news/nation-world/luigi-mangiones-fingerprints-match-prints-found-at-the-scene-of-unitedhealthcare-ceo-brian-thompson-killing-law-enforcement-sources-midtown-manhattan-altoona-pennsylvania-mcdonalds-arrest-health-insurance-motive-forensic-evidence"> Pennsylvania news outlets</a> also reported on Wednesday that Mangioni's fingerprints have been positively matched to those found at the New York City shooting. The fingerprints match those found on a water bottle and candy bar wrapper recovered near the crime scene, the New York Post <a href="https://nypost.com/2024/12/11/us-news/luigi-mangione-in-custody-12-11-2024/">reported</a>, citing a law enforcement official. 
<h2 class="wp-block-heading">Lawyer Says No To Extradition</h2>
Mangione's lawyer, Thomas Dickey, denies his client's involvement in the New York murder, noted CNN, and says Mangione will likely plead not guilty to the murder charge, among other counts. Mangione also plans to plead not guilty to Pennsylvania charges related to the gun and fake ID police found on him, Dickey said.
Read Now:
<ul>
<li><a href="https://www.benzinga.com/news/24/12/42435528/google-removes-negative-reviews-targeting-altoona-mcdonalds-after-arrest-of-suspected-unitedhealthcare-ceo-shooter-tip">Google Removes Negative Reviews Targeting Altoona McDonald&#8217;s After Arrest Of Suspected UnitedHealthcare CEO Shooter Tip</a></li>
</ul>
Photo courtesy of Pennsylvania State Police.

Legal

'Wack The CEO,' United Health Care Murder Suspect Luigi Mangione Says In Papers Found By Police

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) is making waves again, with a notable 10% rally over the past 24 hours spurring bullish <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">predictions on social media</a>.
What Happened: Crypto trader Scofield declared Dogecoin "is back" and stronger than before.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> Is back Stronger than before&#x1f680; <a href="https://t.co/99m2ypMu8Y">pic.twitter.com/99m2ypMu8Y</a>
&mdash; Scofield (@Crypto_Scofield) <a href="https://twitter.com/Crypto_Scofield/status/1866882957459239185?ref_src=twsrc%5Etfw">December 11, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Daan Crypto Trades <a href="https://x.com/DaanCrypto/status/1866830796234903598">observed</a> that DOGE is trading between two major weekly levels from its 2021 run. He emphasized the importance of the $0.35–$0.45 range, with DOGE finding strong support near $0.38. 
He predicts a successful retest of $0.45 will likely lead to a breakout.
Taking a cautious stance, Master Kenobi <a href="https://x.com/btc_MasterPlan/status/1866873137129746480">forecasted</a> a red weekly close followed by two green weeks and a major price pump starting around Dec. 30.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42421654/dogecoin-drops-14-shiba-inu-sinks-17-whats-behind-the-decline">Dogecoin Drops 14%, Shiba Inu Sinks 17%: What&#8217;s Behind The Decline?</a>
Why It Matters: Dogecoin is once again leading trading volumes in the cryptocurrency market, signaling strong investor interest.
Cryptocurrency Inside <a href="https://x.com/Crypto_Inside_/status/1866803273493057888">indicates</a> DOGE tops the charts for trading volume, with $9.52 billion in 24-hour volume outpacing that of Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) at $6.58 billion and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) at $2.24 billion.
Coinglass data reports $17.9 million liquidations in the past 24 hours as open interest spiked by 5.6% to $3.3 billion.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42364596/happy-11th-birthday-dogecoin-trader-anticipates-violent-upside-move-if-3-week-accumulation-breaks">Happy 11th Birthday, Dogecoin! Trader Anticipates &#8216;Violent Upside Move&#8217; If 3-Week Accumulation Breaks</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

'Dogecoin Is Back' With A 10% Single-Day Rally: How High Can DOGE Go?

CG Oncology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) shares are trading lower by 6.02% to $31.67 during Wednesday&#8217;s session. The company announced it filed an underwritten public offering of <a href="https://www.benzinga.com/pressreleases/24/12/g42432311/cg-oncology-announces-proposed-public-offering">7.3 million shares of its common stock</a>.
What To Know: CG Oncology has filed a Form S-1 registration with the SEC for a proposed public offering of 7.3 million shares of common stock. 
Additionally, an existing stockholder plans to sell 700,000 shares in the offering, though CG Oncology will not receive proceeds from those sales. The company may grant underwriters a 30-day option to purchase up to 1.2 million additional shares.
The offering&#8217;s terms, including the public price, remain undetermined and depend on market conditions.
Read Also: <a href="https://www.benzinga.com/24/12/42440806/adobe-q4-earnings-preview-analyst-says-investors-may-be-missing-healthy-subscriber-growth">Adobe Q4 Earnings Preview: Analyst Says Investors May Be Missing Healthy Subscriber Growth</a>
<h2 class="wp-block-heading">Should I Sell My CGON Stock?</h2>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) have decreased by 17.68% in the past year. An investor who bought shares of CG Oncology at the beginning of the year would take a loss of $6.57 per share if they sold it today. The stock has fallen 17.25% over the past month, meaning an investor who bought shares on Nov. 1 would see a capital loss of $6.18.
CG Oncology shares have an all-time high of $47.93, representing 56.63% upside from current levels.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. CG Oncology stock currently has an RSI of 44.21, indicating neutral conditions.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a>
CGON has a 52-week high of $50.23 and a 52-week low of $25.77.

CGON

Why CG Oncology (CGON) Stock Is Down 9%

RBC Capital analyst James McGarragle reiterates Air Canada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AC#TSX">AC</a>) with a Sector Perform and maintains C$22 price target.

TSX:AC

RBC Capital Reiterates Sector Perform on Air Canada, Maintains C$22 Price Target

Barclays analyst Adrienne Yih maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Equal-Weight and lowers the price target from $81 to $79.

Barclays Maintains Equal-Weight on Nike, Lowers Price Target to $79

RBC Capital analyst Michael Harvey reiterates Advantage Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AAV#TSX">AAV</a>) with a Sector Perform and maintains C$11 price target.

Comments

Jyske Bank

Jyske Bank (JYSKF) Forecast

Jyske Bank (OTC:JYSKF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga